The Small Print

The need to produce smaller, more sophisticated drug or drug-delivery particles presents a challenge to pharmaceutical manufacturers. So, how do you guarantee high batch reproducibility and dose uniformity on a commercial scale? Simple – you look to the industries who do it best. Or at least, that’s what Aerie Pharmaceuticals did when they acquired the rights from Envisia Therapeutics, Inc. to use Particle Replication in Non-wetting Templates – also known as PRINT® – technology in October 2017.

Read the full article now

Log in or register to read this article in full and gain access to
The Ophthalmologist’s entire content archive. It’s FREE and always will be!